DYAI · Dyadic International Inc
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $3.81M | $3.09M | $3.5M | $2.9M | $2.93M | $2.4M | $1.6M | $1.68M | $1.3M | |
| — | $2.32M | $1.19M | $1.98M | $2.12M | $1.94M | $1.42M | $1.46M | $1.03M | |
| — | $770.49K | $2.3M | $922.96K | $807.11K | $459.39K | $176.99K | $221.38K | $268.17K | |
| — | 24.93% | 65.82% | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.7% | |
| $476.07K | $2.15M | $2.04M | $3.3M | $4.5M | $8.39M | $3.87M | $3.09M | $2.1M | |
| $5.92M | $5.76M | $6.13M | $5.82M | $6.42M | $6.7M | $6.08M | $5.52M | $4.52M | |
| $10.9M | $10.28M | $9.4M | $11.13M | $13.1M | $17.13M | $11.63M | $10.96M | $8.89M | |
| -$7.09M | -$7.19M | -$5.9M | -$8.23M | -$10.17M | -$14.73M | -$10.03M | -$9.28M | -$7.59M | |
| — | -232.75% | -168.82% | -283.9% | -346.92% | -612.67% | -625.85% | -552.18% | -586.09% | |
| $252.82K | $284.09K | — | — | — | — | — | — | — | |
| -$198.7K | -$171.81K | $91.66K | $1.43M | $430.42K | $1.66M | — | — | $894.53K | |
| — | — | $60.98K | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $31.32K | $10.31K | -$1.01M | |
| -$7.29M | -$7.36M | -$5.81M | -$6.8M | -$9.74M | -$13.07M | -$9.33M | -$8.31M | -$5.69M | |
| — | -238.31% | -166.19% | -234.42% | -332.23% | -543.73% | -582.13% | -494.21% | -439.36% | |
| USD/shares | — | -$0.23 | -$0.20 | -$0.24 | -$0.34 | — | — | — | — |
| USD/shares | — | -$0.23 | — | — | — | — | — | — | — |
| shares | — | — | — | 28.8M | — | 27.84M | 27.47M | 27M | 27.67M |
| shares | — | 32.62M | — | — | — | 27.84M | 27.47M | 27M | 27.67M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2019: $2.3M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 280 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Grant | $1,858,034 | — | — | — | — |
| Research and Development | $967,311 | $1,605,220 | $2,545,865 | $2,683,244 | $2,403,831 |
| License | $265,000 | $890,169 | $352,941 | $247,059 | $0 |